Affiliated with a Castle Connolly Top Hospital
Who is Dr. Levy, Medical Oncologist in Stanford, CA?
Dr. Ronald Levy, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. He is board certified. Dr. Levy graduated from Stanford University School of Medicine and completed his residency at Massachusetts General Hospital. Dr. Levy is fluent in English and Spanish, and is currently seeing new patients. Dr. Levy’s practice accepts Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Levy’s office at (650) 723-4000.
Where did Dr. Levy go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine,Stanford, Ca, United States
Residency: Massachusetts General Hospital | Massachusetts General Hospital Program
Medical School: Stanford University School of Medicine
Is Dr. Levy board certified as a Medical Oncologist?
Yes, Dr. Ronald Levy, MD is board certified by the American Board of Internal Medicine since 1979, American Board of Internal Medicine since 1973
What languages does Dr. Levy speak?
Dr. Levy and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does a Medical Oncologist like Dr. Levy typically treat?
As a Medical Oncologist, Dr. Levy diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Levy. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Lymphoma
- Lymphatic Cancer
- Lymphosarcoma
- NHL
- Follicular Non-Hodgkin Lymphoma
- FL
- Nodular Lymphoma
- MCL
- Mantle Cell Lymphoma Cancer
- Follicular Lymphatic Cancer
- Indolent Lymphoma
ICD-10 Codes:
- C8580: Other specified types of non-Hodgkin lymphoma, unspecified site
- C8290: Follicular lymphoma, unspecified, unspecified site
- C8310: Mantle cell lymphoma, unspecified site
- C8218: Follicular lymphoma grade II, lymph nodes of multiple sites
What procedures does a Medical Oncologist like Dr. Levy typically perform?
As a Medical Oncologist, procedures performed by Dr. Ronald Levy may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
Please contact Dr. Levy's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Levy accept my insurance?
Dr. Levy accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Levy accept in Stanford, CA?
Dr. Levy in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Medicaid
Medicare
UnitedHealth Group
View All Insurances
Where is Dr. Levy's office located?
Recognitions
Publications
High PD-1 expression
, 2013
A vaccine directed to B cells
, 2012
CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T
, 2012
Combition strategies to enhance antitumor ADCC
, 2012
Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28
, 2012
Prolonged disease-free survival
, 2011
Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results
, 2011
The Efficacy of HGAL and LMO2 in the Separation of Lymphom
, 2011
Immunomodulating antibodies and drugs for the treatment of hematological maligncies
, 2011
In Situ Vaccition With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
, 2010
Immunoarchitectural Patterns in Follicular Lymphoma
, 2010
B-cell sigling networks reveal a negative prognostic human lymphoma cell subset that emerges during
, 2010
C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia
, 2010
CD81 protein is expressed at high levels in normal germil center B cells
, 2010
Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma
, 2009
Anti-idiotype antibody response after vaccition correlates with better overall survival in
, 2009
The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms
, 2009
Idiotype vaccition for lymphoma: moving towards optimisation
, 2009
Follicular lymphoma B cells induce the conversion of conventiol CD4
, 2009
Tumor-specific recombint idiotype immunisation after chemotherapy as initial treatment for
, 2009
Neither CD68+Nor CD163+Macrophages Are Associated with Decreased Survival in Follicular Lymphoma
, 2008
LMO2 protein expression predicts survival in patients with diffuse large B
, 2008
Minor BCL2 breakpoints in follicular lymphoma
, 2007
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the
, 2007
Therapeutic vaccition against murine lymphoma by intratumoral injection of recombint fowlpox virus
, 2007
Cell-free production of scFv fusion proteins
, 2007
The oncoprotein LMO2 is expressed in normal germil-center B cells and in human B-cell lymphomas
, 2007
Expression of the R-binding protein VICKZ in normal hematopoietic tissues and neoplasms
, 2007
Expression of the human germil center-associated lymphoma
, 2007
Altered B-cell receptor sigling kinetics distinguish human follicular lymphoma. B cells from tumor
, 2006
Kinetics of B cell receptor sigling
, 2006
Production of myeloid dendritic cells
, 2006
Therapeutic vaccition against murine lymphoma by intratumoral injection of ive dendritic cells
, 2005
Expression of the human germil center-associated lymphoma (HGAL) protein
, 2005
Clinical outcome of lymphoma patients after idiotype vaccition is correlated with humoral immune
, 2004
AID is expressed in germil center B-cell-like
, 2004
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes
, 2004
Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas
, 2004
TCR vaccines against a murine T cell lymphoma
, 2004
Two immunoglobulin G fragment C receptor polymorphisms independently predict response
, 2003
Alysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma
, 2003
Higher grade transformation of follicular lymphoma
, 2003
Diffuse large B-cell lymphoma: Insights gained from gene expression profiling
, 2003
Antitumor immunity after vaccition with B lymphoma cells overexpressing a triad of costimulatory
, 2003
Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid maligncies
, 2003
Variation in gene expression patterns in follicular lymphoma and the response to rituximab
, 2003
Immunogenicity of a plasmid D vaccine encoding chimeric idiotype in patients with B-cell lymphoma
, 2002
BCL-6 mR expression in higher grade transformation of follicle center lymphoma
, 2002
Transformation of follicular lymphoma to diffuse large-cell lymphoma
, 2002
Idiotype-pulsed dendritic cell vaccition for B-cell lymphoma
, 2002
Re: Akasaka, H., et al., Molecular atomy of BCL6 translocations revealed by long
, 2001
Idiotype-encoding recombint adenoviruses provide protective immunity against murine B
, 2001
T cell antigen receptor vaccines for active therapy of T cell maligncies
, 2001
Idiotype vaccition following ABMT can stimulate specific anti
, 2001
The inference of antigen selection on Ig genes
, 2000
A perspective on monoclol antibody therapy: Where we have been and where we are going
, 2000
Rituximab anti-CD20 monoclol antibody therapy in non-Hodgkin's lymphoma
, 2000
Ongoing immunoglobulin somatic mutation in germil center B cell-like but not in activated B cell
, 2000
Combition immunotherapy of relapsed or refractory low-grade or follicular non
, 2000
Recombint adenovirus vaccine encoding a chimeric T
, 2000
Linkage of foreign carrier protein to a self
, 2000
Molecular alysis of immunoglobulin genes in diffuse large B-cell lymphomas
, 2000
Mutation alysis of the 5 ' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma
, 2000
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
, 2000
Idiotype vaccition using dendritic cells after autologous peripheral blood progenitor cell
, 2000
Cytokine fusion constructs as D vaccines against tumors.
, 2000
Karnofsky Lecture: Immunotherapy of lymphoma
, 1999
1999 keystone symposium on B lymphocyte biology and disease: B cell maligncy II session.
Single-agent monoclol antibody efficacy in bulky non-Hodgkin's lymphoma
, 1999
D vaccition against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection
, 1999
Idiotype vaccition using dendritic cells after autologous peripheral blood stem cell
, 1999
TCR vaccines against T cell lymphoma
, 1999
TCR vaccines for active immunotherapy of T cell maligncies
, 1997
Idiotype vaccines for non
, 1997
IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's
, 1997
IDEC-C2B8 (Rituximab) anti-CD20 monoclol antibody therapy in patients with relapsed low-grade
, 1997
Ratiole for adjuvant idiotypic vaccition after high-dose therapy for multiple myeloma.
, 1997
A nine-amino acid peptide from IL-1 beta augments antitumor immune responses induced by protein
, 1996
D immunization induces protective immunity against B-cell lymphoma
, 1996
Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccition for B-cell
, 1996
Surgical resection of large incompletely treated intracranial arteriovenous mal
, 1996
Yttrium-90-labeled anti-CD20 monoclol antibody therapy of recurrent B-cell lymphoma
Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
, 2013
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades
, 2013
Hierarchy in somatic mutations arising during genomic evolution
, 2013
High PD-1 expression
, 2013
Self-antigen recognition by follicular lymphoma B-cell receptors
, 2012
A vaccine directed to B cells
, 2012
CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T
, 2012
Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory
, 2012
Combination strategies to enhance antitumor ADCC
, 2012
Adoptive Cell Therapy for Lymphoma with CD4 T Cells Depleted of CD137-Expressing Regulatory T Cells
, 2012
Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28
, 2012
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy
, 2011
Prediction of survival in diffuse large B
, 2011
Prolonged disease-free survival
, 2011
Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results
, 2011
The Efficacy of HGAL and LMO2 in the Separation of Lymphom
, 2011
Immunomodulating antibodies and drugs for the treatment of hematological malignancies
, 2011
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
, 2011
A CpG-loaded tumor cell vaccine induces antitumor CD4
, 2011
Escherichia coli-based production of a tumor idiotype antibody fragment
, 2011
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
, 2010
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis
, 2010
Immunoarchitectural Patterns in Follicular Lymphoma
, 2010
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges
, 2010
C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia
, 2010
CD81 protein is expressed at high levels in normal germinal center B cells
, 2010
Cell-free production of Gaussia princeps luciferase
, 2009
Generation of CD8(+) T cell-mediated immunity against idiotype-negative lymphoma escapees
, 2009
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion
, 2009
Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant
, 2009
Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma
, 2009
Anti-idiotype antibody response after vaccination correlates with better overall survival in
, 2009
Vaccines for lymphomas: Idiotype vaccines and beyond
, 2009
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need
, 2009
The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms
, 2009
Immunotransplantation preferentially expands T-effector cells over T
, 2009
Idiotype vaccination for lymphoma: moving towards optimisation
, 2009
Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not
, 2009
Follicular lymphoma B cells induce the conversion of conventional CD4
, 2009
Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or
, 2009
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for
, 2009
Neither CD68+Nor CD163+Macrophages Are Associated with Decreased Survival in Follicular Lymphoma
, 2008
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with
, 2008
LMO2 protein expression predicts survival in patients with diffuse large B
, 2008
Minor BCL2 breakpoints in follicular lymphoma
, 2007
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the
, 2007
Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox
, 2007
Cell-free production of scFv fusion proteins
, 2007
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas
, 2007
Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms
, 2007
Humoral immune response
, 2007
Expression of the human germinal center-associated lymphoma
, 2007
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma. B cells from
, 2006
Kinetics of B cell receptor signaling
, 2006
Production of myeloid dendritic cells
, 2006
Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells
, 2005
Expression of the human germinal center-associated lymphoma (HGAL) protein
, 2005
Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system
, 2005
The radioisotope contributes significantly to the activity of radioimmunotherapy
, 2004
Clinical outcome of lymphoma patients after idiotype vaccination
, 2004
Expression of active murine granulocyte-macrophage colony
, 2004
AID is expressed in germinal center B-cell-like
, 2004
Vaccines in lymphoma.
, 2004
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes
, 2004
Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas
, 2004
TCR vaccines against a murine T cell lymphoma
, 2004
Two immunoglobulin G fragment C receptor polymorphisms independently predict response
, 2003
Multiple BCL6 translocation partners in individual cases of gastric lymphoma - Response
, 2003
BCL6 gene translocation in follicular lymphoma
, 2003
Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma
, 2003
The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged
, 2003
Higher grade transformation of follicular lymphoma
, 2003
Diffuse large B-cell lymphoma: Insights gained from gene expression profiling
, 2003
Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory
, 2003
Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies
, 2003
Variation in gene expression patterns in follicular lymphoma and the response to rituximab
, 2003
HGAL is a novel interleukin-4
, 2003
Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma
, 2002
BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma
, 2002
Transformation of follicular lymphoma to diffuse large-cell lymphoma
, 2002
In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma
, 2002
Mutation of the ATM gene is not involved
, 2002
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma
, 2002
Rapid establishment of dendritic cell chimerism
, 2002
BLyS* and BLyS receptor expression in non-Hodgkin's lymphoma
, 2002
Apoptosis stimulating protein of p53
, 2002
A polymorphism in the BCL-6 gene is associated with follicle center lymphoma
, 2001
Re: Akasaka, H., et al., Molecular anatomy of BCL6 translocations revealed by long
, 2001
Expression of complement inhibitors CD46, CD55
, 2001
Expression of a single gene, BCL-6
, 2001
Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B
, 2001
T cell antigen receptor vaccines for active therapy of T cell malignancies
, 2001
Idiotype vaccination following ABMT can stimulate specific anti
, 2001
The inference of antigen selection on Ig genes
, 2000
A perspective on monoclonal antibody therapy: Where we have been and where we are going
, 2000
The history of the development of vaccines for the treatment of lymphoma.
, 2000
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma
, 2000
Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell
, 2000
Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the
, 2000
Combination immunotherapy of relapsed or refractory low-grade or follicular non
, 2000
Recombinant adenovirus vaccine encoding a chimeric T
, 2000
Linkage of foreign carrier protein to a self
, 2000
Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas
, 2000
Mutation analysis of the 5 ' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma
, 2000
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
, 2000
Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell
, 2000
Cytokine fusion constructs as DNA vaccines against tumors.
, 2000
'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns.
, 2000
Karnofsky Lecture: Immunotherapy of lymphoma
, 1999
1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session.
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma
, 1999
DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection
, 1999
Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell
, 1999
TCR vaccines against T cell lymphoma
, 1999
Dendritic cell vaccines for cancer immunotherapy
, 1999
Anti-idiotype antibodies can induce long
, 1998
Stereotactic radiosurgery of angiographically occult vascular malformations: 14-year experience
, 1998
Pathological changes in surgically resected angiographically occult v
, 1998
Identification of peptide lig
, 1998
TCR vaccines for active immunotherapy of T cell malignancies
, 1997
Idiotype vaccines for non
, 1997
IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's
, 1997
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade
, 1997
Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
, 1997
Tumor-specific idiotype vaccines in the treatment of patients with B
, 1997
A nine-amino acid peptide from IL-1 beta augments antitumor immune responses induced by protein
, 1996
DNA immunization induces protective immunity against B-cell lymphoma
, 1996
Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell
, 1996
Surgical resection of large incompletely treated intracranial arteriovenous mal
, 1996
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
What is Dr. Levy's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Levy's National Provider Identifier (NPI) number is 1851427025.
What common questions do patients ask about Dr. Levy?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Levy
What is Dr. Ronald Levy's specialty?
Dr. Levy is a Medical Oncologist near Stanford, CA.
What does a Medical Oncologist do?
An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options.
Is this Dr. Ronald Levy affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Levy is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Medical Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Medical Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Ronald Levy accepting new patients in Stanford, CA?
Yes, Dr. Ronald Levy is accepting new patients at this time.
Does Dr. Ronald Levy offer online booking?
Please contact Dr. Levy's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Ronald Levy?
Please contact Dr. Levy's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Ronald Levy have?
Dr. Ronald Levy is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patients
Medical Oncologist
Accepting patients